This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

rifamycin sodium (Relafalk®)

Reference No. 2034

Publication date:

Appraisal information

rifamycin sodium (Relafalk®) 200 mg modified-release tablet

Company: Dr Falk Pharma UK Ltd
BNF category: Gastro-intestinal system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/06/2020

Current Progress

Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK In the absence of a submission from the holder of the marketing authorisation, rifamycin sodium (Relafalk®) cannot be endorsed for use within NHS Wales for the treatment of traveller’s diarrhoea in adults accompanied by symptoms like nausea, vomiting, gas/flatulence, rectal tenesmus, faecal urgency and abdominal pain or cramps without clinical signs of invasive enteritis such as fever, blood, occult blood or leucocytes in the stools
Statement of Advice (SOA)